Tacrolimus in pediatric renal transplantation: A review

Pediatric Transplantation

Volumn 2, Issue 4, 1998, Pages 270-276

  Shapiro, Ron ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Pediatric; Renal; Review; Tacrolimus; Transplantation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADOLESCENT; CHILD; DRUG ADMINISTRATION; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGY; INFANT; KIDNEY TRANSPLANTATION; METHODOLOGY; PRESCHOOL CHILD; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; SURVIVAL RATE; TACROLIMUS; TREATMENT OUTCOME;

EID: 0032200479     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. STARZL TE, TODO S, FUNG J, et al. FK 506 for liver, kidney, pancreas transplantation. Lancet 1989: 28: 1000-1004.
2. TODO S, FUNG JJ, STARZL TE. Liver, kidney, thoracic organ transplantation under FK506. Ann Surg 1990: 212: 295-305.
3. FUNG JJ, ABU-ELMAGD K, JAIN A, et al. A randomized trial of FK506 VS. cyclosporine. Trans Proc 1991: 23: 2977-2983.
4. KLINTMALM G. US MULTICENTER FK506 LIVER STUDY GROUP. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after liver transplantation. N Engl J Med 1994: 331: 1110-1115.
5. TODO S, FUNG JJ, STARZL TE, et al. Single-center experience with primary orthotopic liver transplantation under FK506 immunosuppression. Ann Surg 1995: 222: 270-280.
6. SHAPIRO R, JORDAN ML, SCANTLEBURY VP, et al. A prospective, randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995: 59: 485-490.
7. SHAPIRO R. Tacrolimus (FK-506) in kidney transplantation. Trans Proc 1997: 29: 45-47.
8. VINCENTI F, LASKOW DA, NEYLAN JF, MENDEZ R, MATAS AJ. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the US. Multicenter FK506 Kidney Transplant Group Transplantation 1996: 61: 1576-1581.
9. LASKOW DA, VINCENTI F, NEYLAN JF, MENDEZ R, MATAS AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: A report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996: 62: 900-905.
10. PIRSCH JD, MILLER J, DEIERHOI MH. et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997: 63: 977-783.
11. MILLER J, PIRSCH JD, DEIERHOI R. FK506 in kidney trans plantation: Results of the U. SA. Randomized Comparative Phase III Study. Trans Proc 1997: 29: 304-305.
12. JORDAN ML, NARAGHI R, SHAPIRO R, et al. Tacrolimus rescue therapy for renal allograft rejection - five year experience. Transplantation 1997: 63: 233-238.
13. OCHIAI T, ISHIBASHI M, FUKAO K, TAKAHASHI K, ENDO T, YOKOYAMA I, UCHIDA K, OHSHIMAS S, TAKAHARA S, MOROZUMI K, YAMAGUCHI Y, KYO M, SONODA T, TAKAGI H, OTA K, IWASAKI Y, THE JAPANESE FK506 STUDY GROUP. Japanese multicenter studies of FK506 in renal transplantation. Trans Proc 1995: 22: 50-51.
14. CIANCIO G, ROTH D, BURKE G, et al. Renal transplantation in a new immunosuppressive era. Trans Proc 1995: 27: 812-813.
15. WOODLE ES, THISTLETHWAITE JR, GORDON JH, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection: A report of the tacrolimus kidney transplantation rescue study group. Transplantation 1996: 62: 594-599.
16. MAYER AD, DMITREWSKI J, SQUIFFLET, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997: 64: 436-443.
17. JENSEN CWB, JORDAN ML, SCHNECK FX, et al. Pediatric renal transplantation under FK 506 immunosuppression. Trans Proc 1991: 23: 3075-3077.
18. SCHNECK FX, JORDAN M, JENSEN CWB, et al. Pediatric RENAL transplantation UNDER FK-506 immunosuppression. Jour of Urol 1992: 147: 1585-1587.
19. SCANTLEBURY V, SHAPIRO R, TZAKIS A, et al. Pediatric Kidney transplantation at the University of Pittsburgh. Transplant Proc 1994: 26: 46-47.
20. ELLIS D, SHAPIRO R, JORDAN ML, et al. Comparison of FK506 and Cyclosporine regimens in pediatric renal transplantation. Pediatric Nephrology, Pediatr Nephrol 1994: 8: 193-200.
21. SHAPIRO R, TZAKIS A, SCANTLEBURY V, et al. Improving results of pediatric kidney transplantation. Journal of the American College of Surgeons, 1994: 179: 424-432.
22. SHAPIRO R, SCANTLEBURY VP, JORDAN ML. et al. FK506 in pediatric kidney transplantation - primary and rescue experience. Pediatric Nephrology 1995: 9: S43-S48.
23. SHAPIRO R, SCANTLEBURY VP, JORDAN ML, et al. Tacrolimus in pediatric renal transplantation. Transplantation 1996: 62: 1752-1758.
24. SHAPIRO R, JORDAN M, FUNG J, et al. Kidney Transplantation under FK 506 immunosuppression. Transplant Proc 1991: 23: 920-923.
25. CARROLL PB, RILO H, REYES J, et al. FK-506 associated diabetes mellitus in the pediatric transplant population is a rare complication. Transplant Proc 1991: 23: 3171-3172.
26. SCANTLEBURY V, SHAPIRO R, FUNG J, et al. New onset of diabetes in FK 506 versus cyclosporine-treated kidney transplant recipients. Transplant Proc 1991: 23: 3169-3170.
27. TZE WJ, TAI J, CHEUNG S. In vitro effects of FK 506 on human and rat islets. Transplantation 1990: 49: 1172-1174.
28. TAMURA K, FUJIMURA T, TSUTSUMI T, et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. Trans Proc 1995: 27: 357-361.
29. TAMURA K, FUJIMURA T, TSUTSUMI, et al. Transcription al inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995: 59: 1601-1613.
30. REDMON JB, OLSON LK, ARMSTRONG MB, GREENE MJ, ROBERTSON RP. Effects of tacrolimus (FK506) on human insulin mRNA levels, insulin secretion in HIT-T15 cells. J Clin Investigation 1996: 98: 2786-2793.
31. MCCAULEY J, TAKAYA S, FUNG J, et al. The question of FK506 nephrotoxicity after liver transplantation. Trans Proc 1991: 23: 1444-1447.
32. STARZL TE, ABU-ELMAGD K, TZAKIS A, FUNG JJ, PORTER KA, TODO S. Selected topics on FK506, with special references to rescue of extraheptic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, practical pharmacokinetics. Trans Proc 1991: 23: 914-919.
33. STARZL TE. FK506 versus cyclosporine. Trans Proc 1993: 25: 511-512.
34. DEMBTRIS AJ, BANNER B, FUNG JJ, et al. Histopathology of human renal allograft function under FK506: a comparison with cyclosporine. Trans Proc 1991: 23: 944-946.
35. RANDHAWA PS, SHAPIRO R, JORDAN ML, STARZL TE, DEMETRIS AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506: clinical significance and comparison with cyclosporine. Am J Surg Pathol 1993: 17: 60-68.
36. SHAPIRO R, FUNG JJ, JAIN AB, PARKS P, TODO S, STARZL TE. The side effects of FK506 in humans. Trans Proc 1990: 22: 35-36.
37. BIRK PE, COOK ME, SCHMIDT WJ, CHAVERS BM. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single-center report. Trans Proc 1996: 28: 993-994.
38. MCKEE M, SEGEV D, WISE B. Initial experience with Fk506 (tacrolimus) in pediatric renal transplant recipients. J Pediatr Surg 1997: 32: 688-690.
39. FURTH S, NEU A, COLOMBANI P. Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. Pediatr Neph 1996: 10: 64-66.
40. OFFNER G, LATTA K, BOKENKAMP A, HOYER PF. Tacrolimus for rescue of renal transplantation in children. The II International Congress on Pediatric Transplantation, August 22-24, Pediatr Neph 1996: 10: C62 (abstract #S18).
41. DUDLEY JA, MCGRAW ME. Tacrolimus (FK506) in resistant acute rejection in paediatric renal transplantation. Pediatr Neph 1996: 10: C62 (abstract #PO13).
42. COREY HE, TELLIS V, SCHECHNER R, GREENSTEIN SM. Improved renal allograft survival in children treated with FK 506 (tacrolimus) rescue therapy. Pediatr Neph 1996: 10: 720-722.
43. HULTON SA, MILFORD DV, TAYLOR CM, HAMBLETON S. Experience of tacrolimus (Prograf) in paediatric renal transplantation. Presented at the International Pediatric Nephrology Association, Athens, Greece, September 1997: C16: O 6.
44. FILLER G, LAMPE D, MAT I, STREHLAU J, EHRICH JHH. Dose recommendations for mycophenolate mofetil (MMF) in combination with tacrolimus (FK506) for vascular rejection in paediatric renal transplantation. Presented at the International Pediatric Nephrology Association, Athens, Greece, September 1997: C13: C 88.
45. CALLIS L, VILA A, SALVA A, LARA E, NIETO J. Results of FK506 in sixteen renal-transplanted paediatric patients. Presented at the International Pediatric Nephrology Association, Athens, Greece, September 1997: C34 P 7.
46. SNYDMAN DR, ed. Proceedings of A Symposium On High-Risk Transplantation. Trans Proc 1994: 26: 45.
47. GREEN M, REYES J, TODO R, ROWE DT. Use of quantitative competitive PCR (QC-PCR) to guide preemptive therapy (PT) against EBV associated post-transplant lymphoproliferative disorders (PTLD) after intestinal transplantation (ITx) in children. Trans Proc 1996: 28: 2759-2760.
48. FILLER G, AMENDT P, VON BREDOW MA, EHRICH JH. Transient diabetes mellitus and peripheral insulin resistance following tacrolimus intoxication in a child after renal transplantation. Nephrology, Dialysis, Trans 1997: 12: 334-336.
49. SHAPIRO R, SCANTLEBURY VP, JORDAN ML, et al. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. Trans Proc 1997: 29: 2737-2738.
50. MOXEY-MIMS MM, KAY C, LIGHT JA, KHER KK. Increased incidence of insulin-dependent mellitus in pediatric renal transplant patients receiving tacrolimus (FK506). Transplantation 1998: 65: 617-619.